Skip to Content

40 Results Found

  • Article
  • Open Access
7 Citations
2,581 Views
14 Pages

Monoclonal Anti-PCSK9 Antibodies: Real-World Data

  • Giulia Guidotti,
  • Viola Liberati,
  • Andrea Sorrentino,
  • Elena Lotti and ,
  • Felice Crudele,
  • Angela Rogolino,
  • Aniello Sammartino,
  • Margherita Slanzi,
  • Anna Maria Gori and
  • Martina Berteotti
  • + 6 authors+ 1 author

3 August 2024

Background: Real-world data on the use of lipid-lowering therapy (LLT) in clinical practice show that about 80% of (very) high-cardiovascular (CV)-risk patients disregard the 2019 European Society of Cardiology (ESC) Guidelines’ recommendations...

(This article belongs to the Section Cardiovascular Medicine)
  • Article
  • Open Access
4 Citations
2,886 Views
13 Pages

PCSK9-Targeting Drugs and Gender: Are There Any Differences?

  • Viola Liberati,
  • Giulia Guidotti,
  • Andrea Sorrentino,
  • Margherita Slanzi and ,
  • Elena Lotti,
  • Felice Crudele,
  • Angela Rogolino,
  • Francesco Alfano,
  • Betti Giusti and
  • Rossella Marcucci
  • + 7 authors+ 2 authors

24 June 2025

Background: Atherosclerotic cardiovascular disease (ASCVD) is often perceived as a male-dominant condition, yet recent European data show that more women live with and die from it. Gender disparities have been reported in the management of dyslipidem...

(This article belongs to the Section Cardiovascular Medicine)
  • Review
  • Open Access
12 Citations
6,979 Views
10 Pages

1 December 2018

This review covers the current knowledge about plant stanol esters as a dietary treatment option for heterozygous familial hypercholesterolemia (he-FH) children. The current estimation of the prevalence of he-FH is about one out of 200–250 pers...

  • Article
  • Open Access
625 Views
12 Pages

Prevalence, Clinical Characteristics, and Therapeutic Underachievement in Familial Hypercholesterolemia: Results from the GRegistry-FH Population-Based Study in Greece

  • Genovefa Kolovou,
  • Stamatis Makrygiannis,
  • Niki Pavlatou,
  • Christina Marvaki and ,
  • Olga Kadda,
  • Aikaterini Marvaki,
  • Petros Kalogeropoulos,
  • Vana Kolovou,
  • Anastasios Tzenalis and
  • Helen Bilianou
  • + 30 authors+ 25 authors

1 July 2026

Background and Aim: Familial hypercholesterolemia (FH) is a genetic disorder leading to severely elevated LDL-C and premature atherosclerotic cardiovascular disease (ASCVD). This study, the GRegistry-FH, provides the first population-based estimation...

(This article belongs to the Special Issue Cardiometabolic Disease and Atherosclerosis: Epidemiology, Prevention, Diagnosis, and Clinical Treatment—2nd Edition)
  • Article
  • Open Access
10 Citations
3,782 Views
13 Pages

Aortic Valvular Disease in Elderly Subjects with Heterozygous Familial Hypercholesterolemia: Impact of Lipid-Lowering Therapy

  • Victoria Marco-Benedí,
  • Martin Laclaustra,
  • Juan M. Casado-Dominguez,
  • Rosa Villa-Pobo and ,
  • Rocío Mateo-Gallego,
  • Rosa M. Sánchez-Hernández,
  • Marta Blanco Nuez,
  • Emilio Ortega-Martínez de Victoria,
  • Marta Sitges and
  • Fernando Civeira
  • + 8 authors+ 3 authors

14 December 2019

Hypercholesterolemia and statins are risk factors for aortic stenosis (AS) and vascular calcification, respectively. Whether heterozygous subjects with familial hypercholesterolemia (HeFH) treated with statins are at risk of AS is unknown. We study t...

(This article belongs to the Section Cardiology)
  • Article
  • Open Access
9 Citations
3,459 Views
9 Pages

Cascade Screening and Treatment Initiation in Young Adults with Heterozygous Familial Hypercholesterolemia

  • Amy L. Peterson,
  • Matthew Bang,
  • Robert C. Block,
  • Nathan D. Wong and
  • Dean G. Karalis

13 July 2021

Heterozygous familial hypercholesterolemia (HeFH) creates elevated low-density lipoprotein cholesterol (LDL-C), causing premature atherosclerotic cardiovascular disease (ASCVD). Guidelines recommend cascade screening relatives and starting statin the...

(This article belongs to the Special Issue The Risk Factors of Cardiovascular Diseases)
  • Article
  • Open Access
38 Citations
4,960 Views
12 Pages

The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study

  • Alexey N. Meshkov,
  • Alexandra I. Ershova,
  • Anna V. Kiseleva,
  • Svetlana A. Shalnova and ,
  • Oxana M. Drapkina,
  • Sergey A. Boytsov and
  • on behalf of the FH-ESSE-RF Investigators
  • + 2 authors+ 0 author

Heterozygous familial hypercholesterolemia (HeFH) is one of the most common genetic conditions but remains substantially underdiagnosed. The aim of our study was to investigate the prevalence of HeFH in the population of 11 different regions of Russi...

(This article belongs to the Section Epidemiology)
  • Article
  • Open Access
1 Citations
2,824 Views
5 Pages

Cataract Surgery in Elderly Subjects with Heterozygous Familial Hypercholesterolemia in Prolonged Treatment with Statins

  • Victoria Marco-Benedí,
  • Martín Laclaustra,
  • Rosa M. Sánchez-Hernández,
  • Emilio Ortega-Martínez de Victoria and ,
  • Juan Pedro-Botet,
  • Jose Puzo and
  • Fernando Civeira
  • + 2 authors+ 0 author

8 August 2021

Background: Cataracts are the main cause of blindness and represent one fifth of visual problems worldwide. It is still unknown whether prolonged statin treatment favors the development of cataracts. We aimed to ascertain the prevalence of cataract s...

(This article belongs to the Section Ophthalmology)
  • Article
  • Open Access
2 Citations
3,328 Views
12 Pages

Risk Factors and Modifiers for Cardiovascular Disease Assessment of Patients with Heterozygous Familial Hypercholesterolaemia

  • Richard Malone,
  • Sarah Savage,
  • Vivion Crowley,
  • Martina Hennessy and ,
  • Patricia O’Connor and
  • Cormac Kennedy
  • + 1 author+ 0 author

14 April 2024

Background: The assessment of the risk of cardiovascular disease (CVD) in patients with heterozygous familial hypercholesterolemia (HeFH) is determined by conventional risk factors. However, factors modifying CVD, or risk modifiers, beyond convention...

(This article belongs to the Section Cardiology)
  • Article
  • Open Access
8 Citations
2,922 Views
12 Pages

Sphingosine 1-Phosphate and Apolipoprotein M Levels and Their Correlations with Inflammatory Biomarkers in Patients with Untreated Familial Hypercholesterolemia

  • Lilla Juhász,
  • Hajnalka Lőrincz,
  • Anita Szentpéteri,
  • Bíborka Nádró and ,
  • Éva Varga,
  • György Paragh and
  • Mariann Harangi
  • + 2 authors+ 0 author

15 November 2022

High-density lipoprotein (HDL)-bound apolipoprotein M/sphingosine 1-phosphate (ApoM/S1P) complex in cardiovascular diseases serves as a bridge between HDL and endothelial cells, maintaining a healthy endothelial barrier. To date, S1P and ApoM in pati...

(This article belongs to the Section Biochemistry)
  • Article
  • Open Access
18 Citations
3,301 Views
13 Pages

Oral Porphyromonas gingivalis and Fusobacterium nucleatum Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia

  • Maria Cristina Curia,
  • Pamela Pignatelli,
  • Domenica Lucia D’Antonio,
  • Damiano D’Ardes and ,
  • Elena Olmastroni,
  • Luca Scorpiglione,
  • Francesco Cipollone,
  • Alberico Luigi Catapano,
  • Adriano Piattelli and
  • Paolo Magni
  • + 6 authors+ 1 author

Background: Low-grade chronic inflammation, promoted by dysbiosis of the gut and oral microbiota, has been shown to contribute to individual susceptibility to atherosclerotic cardiovascular disease (ASCVD). High oral Porphyromonas gingivalis (Pg) and...

(This article belongs to the Special Issue Host-Microbiome Crosstalk in Cardiometabolic Diseases)
  • Review
  • Open Access
22 Citations
5,046 Views
11 Pages

Familial Hypercholesterolemia: Do HDL Play a Role?

  • Juan Pedro-Botet,
  • Elisenda Climent and
  • David Benaiges

Cardiovascular disease (CVD) in heterozygous familial hypercholesterolemia (HeFH), the most frequent monogenic disorder of human metabolism, is largely driven by low-density lipoprotein (LDL) cholesterol concentrations. Since the CVD rate differs con...

(This article belongs to the Special Issue High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad, and the Future II)
  • Article
  • Open Access
1 Citations
2,341 Views
14 Pages

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia

  • Ewelina Woźniak,
  • Agnieszka Woźniak,
  • Agnieszka Pawlos,
  • Marlena Broncel and ,
  • Joanna Satała,
  • Bożena Bukowska and
  • Paulina Gorzelak-Pabiś
  • + 2 authors+ 0 author

29 October 2025

Heterozygous familial hypercholesterolemia (HeFH) is a common autosomal dominant genetic disease (1:250) characterized by elevated LDL-C. Patients with HeFH are at increased risk of premature atherosclerosis and have at least a 10-fold greater chance...

(This article belongs to the Special Issue Molecular Pharmacology of Cardiovascular Disease, 2nd Edition)
  • Communication
  • Open Access
5 Citations
2,694 Views
9 Pages

Resilient Older Subjects with Heterozygous Familial Hypercholesterolemia, Baseline Differences and Associated Factors

  • Elisenda Climent,
  • Antón González-Guerrero,
  • Victoria Marco-Benedí,
  • María-del-Mar García-Andreu and ,
  • Juan Diego Mediavilla-García,
  • Manuel Suárez-Tembra,
  • David Benaiges,
  • Xavier Pintó and
  • Juan Pedro-Botet
  • + 4 authors+ 0 author

Despite elevated low-density lipoprotein (LDL) cholesterol levels, some older subjects with heterozygous familial hypercholesterolemia (HeFH) do not develop atherosclerotic cardiovascular disease (ACVD) during their lifetime. The factors related to t...

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Article
  • Open Access
2 Citations
1,504 Views
20 Pages

Lipidomic Signature of Patients with Familial Hypercholesterolemia Carrying Pathogenic Variants Unveils a Cue of Increased Cardiovascular Risk

  • Giulia De Simone,
  • Maria Donata Di Taranto,
  • Debora Paris,
  • Martina Ferrandino and ,
  • Marco Andolfi,
  • Annalaura Iodice,
  • Giovanna Cardiero,
  • Carmine De Luca,
  • Luigi Junior Valletta and
  • Adele Cutignano
  • + 9 authors+ 4 authors

3 November 2025

Familial Hypercholesterolemia (FH) is a common genetic disorder characterized by elevated LDL-cholesterol levels and an increased risk of premature cardiovascular disease. While pathogenic variants in LDLR, APOB, and PCSK9 are well-established causes...

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Article
  • Open Access
2 Citations
2,074 Views
12 Pages

Coronary Artery Calcium Is Independently Associated with Arterial Stiffness and LDL Cholesterol Burden in Patients with Familial Hypercholesterolemia

  • Alessandro Mattina,
  • Antonina Giammanco,
  • Davide Noto,
  • Giulio Geraci and ,
  • Emilio Nardi,
  • Carlo Maria Barbagallo,
  • Carola Maria Gagliardo,
  • Maria Ausilia Giusti,
  • Francesco D’Ignoto and
  • Maurizio Averna
  • + 11 authors+ 6 authors

13 February 2025

Background: Familial hypercholesterolemia (FH) is a genetic disorder characterized by high plasma levels of low-density lipoprotein cholesterol (LDL-C) and exposing patients to higher risk of early cardiovascular (CV) atherosclerotic diseases. Though...

(This article belongs to the Special Issue Personalized Medicine for the Management of Non-Communicable Disease (NCDs))
  • Article
  • Open Access
2 Citations
3,878 Views
11 Pages

Echocardiographic Calcium Score of Aortic Valve Correlates with Coronary Artery Calcium Score in Heterozygous Familial Hypercholesterolemia

  • Angelo Baldassare Cefalù,
  • Emilio Nardi,
  • Antonina Giammanco,
  • Carola Maria Gagliardo and ,
  • Carlo Maria Barbagallo,
  • Ludovico La Grutta,
  • Patrizia Toia,
  • Federica Brucato,
  • Chiara Scrimali and
  • Maurizio Averna
  • + 10 authors+ 5 authors

20 March 2025

Background: Patients with heterozygous familial hypercholesterolemia (HeFH) are at a high risk of atherosclerotic cardiovascular disease. The coronary artery calcification (CAC) score by the Ct-scan Agatston calcium score (ACS) > 100 classifies FH...

(This article belongs to the Section Medical Research)
  • Article
  • Open Access
21 Citations
3,811 Views
13 Pages

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy

  • Arianna Toscano,
  • Maria Cinquegrani,
  • Michele Scuruchi,
  • Antonino Di Pino and ,
  • Salvatore Piro,
  • Viviana Ferrara,
  • Carmela Morace,
  • Alberto Lo Gullo,
  • Egidio Imbalzano and
  • Giuseppe Mandraffino
  • + 8 authors+ 3 authors

9 April 2022

Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) metabolism involved in the degradation of the low-density lipoprotein receptor (LDLR) through complex mechanisms. The PCSK9 plasma levels change...

(This article belongs to the Special Issue Emerging Circulating Biomarkers in Atherosclerosis: From Molecular Mechanisms to Therapeutic Strategies)
  • Article
  • Open Access
5 Citations
2,232 Views
11 Pages

Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid Units

  • Roberto Scicali,
  • Giuseppe Mandraffino,
  • Michele Scuruchi,
  • Alberto Lo Gullo and ,
  • Antonino Di Pino,
  • Viviana Ferrara,
  • Carmela Morace,
  • Caterina Oriana Aragona,
  • Giovanni Squadrito and
  • Salvatore Piro
  • + 6 authors+ 1 author

Background: Circulating CD34+ progenitor cells (CD34+CPCs) are characterized by pronounced tissue regeneration activity. Dyslipidemic subjects seemed to have reduced CD34+CPCs, and statin therapy appeared to restore their levels. We aimed to evaluate...

(This article belongs to the Special Issue Advanced and Innovative Therapies of Dyslipidemia)
  • Article
  • Open Access
2 Citations
2,213 Views
10 Pages

Carotid Artery Temperature Reduction with Statin Therapy in Patients with Familial Hyperlipidemia Syndromes

  • Georgios Benetos,
  • Spyros Galanakos,
  • Iosif Koutagiar,
  • Ioannis Skoumas and ,
  • Georgios Oikonomou,
  • Maria Drakopoulou,
  • Maria Karmpalioti,
  • Vasiliki Katsi,
  • Costas Tsioufis and
  • Konstantinos Toutouzas
  • + 5 authors+ 0 author

27 October 2021

Background: Microwave radiometry (MWR) assesses non-invasive carotid artery temperatures reflecting inflammation. In the present study, we aimed to investigate the impact of hypolipidemic therapy either with simvastatin or with combination simvastati...

(This article belongs to the Section Cardiovascular Medicine)
  • Communication
  • Open Access
4 Citations
2,829 Views
11 Pages

Metabolomic Approach to Screening Homozygotes in Chinese Patients with Severe Familial Hypercholesterolemia

  • Zhiyong Du,
  • Yunhui Du,
  • Linyi Li,
  • Haili Sun and ,
  • Chaowei Hu,
  • Long Jiang,
  • Luya Wang and
  • Yanwen Qin
  • + 3 authors+ 0 author

6 January 2023

Homozygous familial hypercholesterolemia (HoFH) is a rare inborn-errors-of-metabolism disorder characterized by devastatingly elevated low-density lipoprotein cholesterol (LDL-C) and premature cardiovascular disease. The gold standard for screening a...

(This article belongs to the Special Issue Dyslipidemia and Cardiovascular Disease)
  • Review
  • Open Access
36 Citations
13,587 Views
26 Pages

16 June 2023

Since the discovery of the LDL receptor in 1973 by Brown and Goldstein as a causative protein in hypercholesterolemia, tremendous amounts of effort have gone into finding ways to manage high LDL cholesterol in familial hypercholesterolemic (HoFH and...

(This article belongs to the Collection Cardiovascular Disease: From Molecular and Cellular Mechanisms to Therapeutic Opportunities)
  • Systematic Review
  • Open Access
18 Citations
7,649 Views
15 Pages

15 January 2021

Background: Conclusive data on the effectiveness of dietary interventions in heterozygous familial hypercholesterolemia (HeFH) management are unavailable. Whether this is due to a true lack of effects or biases in intervention designs remains unsettl...

(This article belongs to the Special Issue Dietary Influence on Adipose Tissue Metabolism and Blood Lipid Levels)
  • Article
  • Open Access
45 Citations
4,607 Views
12 Pages

Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways

  • Vittoria Cammisotto,
  • Francesco Baratta,
  • Valentina Castellani,
  • Simona Bartimoccia and ,
  • Cristina Nocella,
  • Laura D’Erasmo,
  • Nicholas Cocomello,
  • Cristina Barale,
  • Roberto Scicali and
  • Pasquale Pignatelli
  • + 14 authors+ 9 authors

Background: Proprotein convertase subtilisin kexin type 9 inhibitors (PCSK9i) lower LDL-cholesterol and slow atherosclerosis preventing cardiovascular events. While it is known that circulating PCSK9 enhances platelet activation (PA) and that PCSK9i...

(This article belongs to the Special Issue Molecular Research on Platelet Function in Disease)
  • Article
  • Open Access
25 Citations
3,621 Views
11 Pages

Evaluation of Oxidative Stress Status in Familial Hypercholesterolemia

  • Shiva Ganjali,
  • Reihaneh Keshavarz,
  • Susan Hosseini,
  • Atena Mansouri and ,
  • Massimo R. Mannarino,
  • Matteo Pirro,
  • Tannaz Jamialahmadi and
  • Amirhossein Sahebkar
  • + 3 authors+ 0 author

14 December 2021

Background: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder characterizied by elevated levels of circulating low-density lipoprotein cholesterol (LDL-C) which is an important source of substrates to be oxidized by differe...

(This article belongs to the Section Hematology)
  • Review
  • Open Access
38 Citations
11,799 Views
14 Pages

6 February 2023

Genetics of Familial Hypercholesterolemia (FH) is ascribable to pathogenic variants in genes encoding proteins leading to an impaired LDL uptake by the LDL receptor (LDLR). Two forms of the disease are possible, heterozygous (HeFH) and homozygous (Ho...

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Article
  • Open Access
1 Citations
2,244 Views
14 Pages

Decreased Serum Stromal Cell-Derived Factor-1 in Patients with Familial Hypercholesterolemia and Its Strong Correlation with Lipoprotein Subfractions

  • Lilla Juhász,
  • Hajnalka Lőrincz,
  • Anita Szentpéteri,
  • Nóra Tóth and ,
  • Éva Varga,
  • György Paragh and
  • Mariann Harangi
  • + 2 authors+ 0 author

18 October 2023

Stromal cell-derived factor-1 (SDF-1) is a chemokine that exerts multifaceted roles in atherosclerosis. However, its association with hyperlipidemia is contradictory. To date, serum SDF-1 and its correlations with lipid fractions and subfractions in...

(This article belongs to the Special Issue Dyslipidemia and Related Diseases)
  • Article
  • Open Access
8 Citations
3,106 Views
15 Pages

Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia

  • Bíborka Nádró,
  • Hajnalka Lőrincz,
  • Lilla Juhász,
  • Anita Szentpéteri and ,
  • Ferenc Sztanek,
  • Éva Varga,
  • Dénes Páll,
  • György Paragh and
  • Mariann Harangi
  • + 4 authors+ 0 author

Background: Familial hypercholesterolemia (FH) is an autosomal dominant trait characterized by elevated LDL-C concentrations and is associated with an increased risk of premature atherosclerosis. Progranulin (PGRN) is a multifunctional protein that i...

(This article belongs to the Special Issue Lipids and Lipoproteins in Atherosclerosis: A Commemorative Issue in Honor of Dr. Vladimir V Tertov)
  • Case Report
  • Open Access
9 Citations
3,753 Views
9 Pages

Sudden Cardiac Death Caused by a Fatal Association of Hypertrophic Cardiomyopathy (MYH7, p.Arg719Trp), Heterozygous Familial Hypercholesterolemia (LDLR, p.Gly343Lys) and SARS-CoV-2 B.1.1.7 Infection

  • Nicola Marziliano,
  • Alessandro Medoro,
  • Donatella Mignogna,
  • Giovanni Saccon and ,
  • Stefano Folzani,
  • Claudio Reverberi,
  • Claudio Russo and
  • Mariano Intrieri
  • + 3 authors+ 0 author

Hypertrophic cardiomyopathy (HCM) and heterozygous familial hypercholesterolemia (HeFH), two of the most common genetic cardiovascular disorders, can lead to sudden cardiac death. These conditions could be complicated by concomitant severe acute resp...

(This article belongs to the Section Pathology and Molecular Diagnostics)
  • Article
  • Open Access
16 Citations
5,064 Views
10 Pages

Analytical Validation of Familial Hypercholesterolemia Biomarkers in Dried Blood Spots

  • Patrice K. Held,
  • Kristin Campbell,
  • Amy E. Wiberley-Bradford,
  • Michael Lasarev and ,
  • Vanessa Horner and
  • Amy Peterson
  • + 1 author+ 0 author

Heterozygous familial hypercholesterolemia (HeFH) is a common, treatable genetic disorder characterized by premature atherosclerosis and cardiovascular disease, yet the majority of affected individuals remain undiagnosed. Newborn screening could play...

  • Article
  • Open Access
11 Citations
2,508 Views
11 Pages

29 January 2023

This study aimed to evaluate the high-density lipoprotein (HDL) capacity to efflux cellular cholesterol from lipid-loaded macrophages to find a reliable and low-cost biomarker with the purpose of better evaluating the risk of premature cardiovascular...

(This article belongs to the Special Issue The Role of Lipid Metabolism in Dyslipidemias and Atherosclerosis)
  • Article
  • Open Access
1 Citations
1,176 Views
11 Pages

25-Year Comparison of Coronary Lesions Anatomy in Two Cohorts of French Canadians with Familial Hypercholesterolemia

  • Alex Lauziere,
  • Diane Brisson,
  • Gérald Tremblay,
  • Sophie Bedard and ,
  • Etienne Khoury and
  • Daniel Gaudet
  • + 1 author+ 0 author

7 January 2025

Background: Over the past decades, new treatments and guidelines have been introduced for the screening and management of familial hypercholesterolemia (FH). However, the impact of these medical and scientific advances on the characteristics and burd...

(This article belongs to the Section Cardiovascular Medicine)
  • Article
  • Open Access
12 Citations
591 Views
10 Pages

Background: An elevated level of low-density lipoprotein cholesterol (LDL-C) constitutes one of the most important modifiable risk factors for cardiovascular disease (CVD). Individuals with heterozygous familial hypercholesterolaemia (HeFH) are parti...

  • Systematic Review
  • Open Access
8 Citations
6,560 Views
17 Pages

8 October 2024

Background and Objectives: The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab are recently developed promising drugs used for treatment of familial hypercholesterolemia (FH). This systematic review and meta...

(This article belongs to the Section Cardiology)
  • Article
  • Open Access
1,152 Views
13 Pages

Evaluation of Classical and New Clinical Criteria for Diagnosing Familial Hypercholesterolemia in Childhood

  • Raffaele Buganza,
  • Giulia Massini,
  • Cecilia Nobili,
  • Martina Ferrandino and ,
  • Maria Donata Di Taranto,
  • Luisa de Sanctis and
  • Ornella Guardamagna
  • + 2 authors+ 0 author

Background: Heterozygous familial hypercholesterolemia (HeFH) is characterized by elevated low-density lipoprotein cholesterol (LDL-C) and increased cardiovascular risk, making early diagnosis essential; however, the diagnostic performance of pediatr...

(This article belongs to the Section Cardiovascular Genetics in Clinical Practice)
  • Article
  • Open Access
4 Citations
3,839 Views
14 Pages

Background/Objectives: Hypercholesterolemia, accompanied by vascular inflammation, leads to the premature initiation and progression of atherosclerosis, and both are considered nowadays as well-established cardiovascular (CV) risk factors. For severa...

(This article belongs to the Special Issue Advancements in Cardiovascular and Antidiabetic Drug Therapy, 2nd Edition)
  • Review
  • Open Access
21 Citations
11,803 Views
25 Pages

Unveiling Familial Hypercholesterolemia—Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy

  • Piotr Fularski,
  • Joanna Hajdys,
  • Gabriela Majchrowicz,
  • Magdalena Stabrawa and ,
  • Ewelina Młynarska,
  • Jacek Rysz and
  • Beata Franczyk
  • + 2 authors+ 0 author

29 January 2024

Familial hypercholesterolemia (FH) is a genetic disorder primarily transmitted in an autosomal-dominant manner. We distinguish two main forms of FH, which differ in the severity of the disease, namely homozygous familial hypercholesterolemia (HoFH) a...

(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
  • Systematic Review
  • Open Access
1 Citations
2,410 Views
17 Pages

Enlicitide (MK-0616) is an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for the treatment of hypercholesterolemia. We conducted the first systematic review and meta-analysis evaluating the efficacy and safety of enlicitide acr...

(This article belongs to the Special Issue Lipid and Lipoprotein Metabolism in Cardiovascular Disease)
  • Review
  • Open Access
14 Citations
5,035 Views
12 Pages

How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment

  • Sibbeliene E. van den Bosch,
  • Willemijn E. Corpeleijn,
  • Barbara A. Hutten and
  • Albert Wiegman

7 March 2023

Familial hypercholesterolemia (FH) is a hereditary disorder that causes severely elevated low-density lipoprotein (LDL-C) levels, which leads to an increased risk for premature cardiovascular disease. A variety of genetic variants can cause FH, namel...

(This article belongs to the Section Human Genomics and Genetic Diseases)
  • Review
  • Open Access
569 Views
43 Pages

29 August 2026

Despite major advances in lipid-lowering therapies, a significant unmet need remains, particularly for patients with homozygous familial hypercholesterolemia (HoFH), severe heterozygous familial hypercholesterolemia (HeFH), and those who fail to achi...

(This article belongs to the Special Issue The Evolving Landscape of Cell and Gene Therapy—Opportunities, Challenges and the Road Ahead)